REAL WORLD EVIDENCE NEEDS IN ONCOLOGY: NSCL Cancer White Paper based on new trial results from ESMO Congress, 20-24 October 2023, Madrid. NSCLC’s complex nature, characterized by diverse pathological profiles and variable responses to treatments, underscores the need for ongoing research and innovation in treatment strategies. OXON has analyzed the results of the studies presented…
Read more
REAL WORLD EVIDENCE NEEDS IN ONCOLOGY: Prostate Cancer White Paper based on new trial results from ESMO Congress, 20-24 October 2023, Madrid. As the second most common cancer in men worldwide, prostate cancer poses substantial healthcare burdens and necessitates continuous research and innovation in treatment strategies. OXON has analyzed the results of the trials presented…
Read more
REAL WORLD EVIDENCE NEEDS IN ONCOLOGY: Non-Prostate Urothelial Cancer White Paper based on new trial results from ESMO Congress, 20-24 October 2023, Madrid. In the dynamic landscape of oncology, non-prostate urothelial cancers, encompassing bladder and urinary tract malignancies, present unique challenges in clinical management. By synthesizing insights from the ESMO 2023 conference and broader oncological…
Read more
REAL WORLD EVIDENCE NEEDS IN ONCOLOGY: Melanoma White Paper based on new trial results from ESMO Congress, 20-24 October 2023, Madrid. Advancements in melanoma therapies presented at ESMO 2023 mark a shift, where the integration of innovative treatments with real-world data is paving the way for more personalized and effective care in melanoma. In this…
Read more
The study, published in Lancet Healthy Longevity, suggests that high levels of cholesterol in middle-age are associated with an increased risk of developing dementia and Alzheimer’s disease. The retrospective cohort study ‘Blood cholesterol and risk of dementia in a retrospective cohort of over 1.8 million people over two decades’, presented at the 35th International Conference…
Read more
